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ABSTRACT 
Large cost variations of liver transplantation are reported. The aim of this study was to 
assess cost differences of liver transplantation and clinical follow-up between the United 
States and other Organization for Economic Cooperation and Development (OECD) 
countries. Eight electronic databases were searched, and 2000 citations published after 
1990 with more than 10 transplantations, and with original cost data, were identified. A 
total of 30 articles included 5975 liver transplantations. Meta-analysis was used to derive 
a combined mean using a random-effects model to test for heterogeneity between 
studies. Estimated mean cost of a U.S. liver transplantation was US$ 163 438 
(US$ 145 277 - 181 598) compared to US$ 103 548 (US$ 85 514 - 121 582) for other OECD 
countries. Patient characteristics, disease characteristics, quality of the health care 
provider, and methodology could not explain this cost difference. Health system 
characteristics differed between the United States and other OECD countries. Cost 
differences in liver transplantation between these two groups may be largely explained by 




Total health care spending exceeded inflation in each of the 30 member countries of the 
Organization for Economic Cooperation and Development (OECD) during the period 1992 - 
2006. Annual growth in health care spending per capita averaged 3.4% in the OECD1. 
Therefore, health care is increasingly facing budget restraint; hence, optimal allocation of 
resources is imperative. Cost of health care differs between countries with the United 
States spending more on health care in absolute and relative terms than any other 
developed country2. Concern about the increasing cost of health care has drawn special 
attention to expensive treatments benefiting only a relatively small group of patients3. 
Liver transplantation is one of those expensive treatments for the following reasons: (a) 
Patient selection requires an extensive diagnostic evaluation in a multidisciplinary team; 
(b) organ procurement generates high costs due to the deployment of expert teams and 
the need for transportation of the team and the donor liver over considerable distances; 
(c) the surgical procedure is complex requiring highly trained medical personnel, 
frequently working night and weekend shifts; (d) morbidity after transplantation is high 
with need for radiological and surgical reinterventions as well as prolonged use of 
medication; and finally(e) readmissions and even retransplantations are not uncommon4,5. 
However, these high costs are offset by large gains in health and quality-adjusted life 
years for liver-transplant recipients5,6. In 2007, the worldwide rate was 88% one-year 
patient survival and 74% five-year patient survival (European Liver Transplant Registry, 
Organ Procurement and Transplantation Network)7,8. Due to this favorable outcome, liver 
transplantation has become the established therapy for patients with end-stage liver 
disease. These patients would otherwise survive only several weeks up to a few years 
because of absence of an alternative treatment. 
The first article on the cost-effectiveness of liver transplantation was published in 19909. 
Since then, several articles have been published in which costs relevant for liver 
transplantation were presented. Articles from the United States seemed to report higher 
cost of liver transplantation than articles from other countries. However, reasons for this 
cost difference are unexplored. Interestingly, survival after liver transplantation seemed 
similar between the United States and peer countries10. 
The first aim of this study was to compare cost of liver transplantation between the 
United States and other countries from the OECD in a systematic review. The United 
States was chosen because of the high reported cost of liver transplantation, and the 
other OECD countries were chosen as a comparison because these countries have similar 
levels of development, economy, technology, and health care compared to the United 
States. The OECD consists of 30 democracies, most of which are considered to be the most 
economically advanced countries in the world. 
The second aim of this study was to perform a meta-analysis on the cost data generated 
by the systematic review. This meta-analysis estimated whether the cost difference 
between the United States and the other OECD countries was a real difference. The 
choice of a model was based on the expected amount of heterogeneity11. 
The third aim of this study was to analyze the reasons for the difference in estimated 
costs between the United States and other OECD countries. 
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A systematic literature review written by Goeree et al. identified 77 unique factors that 
may potentially affect the transferability of economic evaluations from one country to 
another12. They grouped these 77 factors into five broad categories enabling 
comprehensive comparison of costs between countries. These five broad categories were 
used in this study and comprised characteristics related to the patient, disease, quality of 
the provider of the treatment, health care system, and methodology used in the economic 
evaluation12. For each of these five categories a comparison on cost of liver 
transplantation was made between the United States and the other OECD countries. 
 
 
2 MATERIALS AND METHOD 
2.1 Systematic review 
All relevant prospective and retrospective studies that reported on cost, cost-
effectiveness, or cost-utility of liver transplantation, published between 1990 and 2006, 
were identified. First, the following registers were searched for details of unpublished and 
ongoing systematic reviews or meta-analyses: National Research Register (NRR), Medical 
Research Council (MRC)–funded research database, Centre for Reviews and Dissemination 
(CRD) register of reviews, Center Watch Clinical Trials Listing Service, and National 
Institutes of Health (NIH) clinical trials databases. No unpublished or ongoing reviews or 
meta-analyses regarding cost of liver transplantation were indexed in these sources. As far 
as we know, no systematic reviews or meta-analyses on cost-effectiveness of liver 
transplantation have been conducted. 
Second, the following electronic databases were searched: Medline, Embase.com, the 
Cochrane Central Register of Controlled Trials (CCTR), the Cochrane Database of 
Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), Health 
Technology Assessment (HTA) Database, National Health Service Economic Evaluation 
Database, and the Cumulative Index to Nursing & Allied Health Literature (CINAHL). 
Medical subject heading (MeSH) as well as free text searching was used to improve the 
sensitivity of the search. Search strings used were “liver transplantation” in combination 
with “cost,” “costs,” “cost-effectiveness,” or “cost-utility.” Searching took place 
between September 2006 and April 2007. No language restriction was applied on 
searching. The reference lists of selected articles were examined. 
The potentially relevant citations were assessed according to title and abstract. From all 
citations that appeared relevant the full articles were retrieved and read in full. Articles 
based on patients undergoing combined organ transplantation were excluded, as were 
articles with costs based on less than 10 patients, and articles without complete 
information on the cost of transplantation and clinical follow-up. Articles from countries 
not belonging to the OECD were excluded. Finally, to allow for cost differences between 
patients within a study, articles without original cost data based on individual patients 
were also excluded, thereby eliminating articles using fixed fees for a liver 
transplantation. The search strategy was tested by hand searching two journals in which 
relevant articles were expected (articles of American Journal of Transplantation and 
Liver Transplantation published between 2002 and 2006). 
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Data were extracted using a standard extraction sheet including first author, year of 
publication, number of patients included, years of patient inclusion, country of 
transplantation, mean costs, method of cost assessment, professional fees, recipient 
indication, recipient age, adult or pediatric recipient, deceased or living donor, and 
primary or retransplantation. When two publications were based on a single group of 
patients, the most detailed publication was used to extract data. The other publication 
was used to provide additional information. 
 
2.2 Meta-analysis 
A meta-analysis was performed with all articles reporting measures of spread around the 
mean, such as standard deviation, standard error, or confidence intervals. Due to the 
expected heterogeneity, the random-effects model was chosen instead of the fixed-effect 
model. A 95% confidence interval (95% CI) around the mean was estimated for the pooled 
cost of the United States and the other OECD countries, respectively. Heterogeneity was 
assessed by the Q value with the corresponding p-value and the I2 quantity11. 
A second meta-analysis was performed to include all articles selected in the systematic 
review. The standard deviation for studies without measures of spread was derived from 
the mean standard deviation of the United States and the other OECD countries, 
respectively. The random-effects model was applied to the data to assess the differences 
with the original model. The results from the second meta-analysis were used to further 
compare cost between the United States and other OECD countries. The meta-analysis was 
performed by using the software Comprehensive Meta Analysis (version 2.2.046, Biostat, 
Englewood, NJ). 
 
2.3 Comparison of study characteristics 
The reasons for the differences in cost of liver transplantation between the United States 
and other OECD countries were analyzed after the meta-analysis. This analysis was 
performed by comparing five broad categories: patient characteristics, disease 
characteristics, quality of the provider of treatment, health care system, and 
methodological characteristics of the economic evaluation12. 
Patient characteristics were examined by looking at the difference in age, gender, and 
the percentage of transplantations for adults and children between the United States and 
other OECD countries13. 
Because the focus of this study was on the costs generated during the liver transplantation 
procedure and the clinical follow-up, patient characteristics, such as attitude toward 
treatment, lifestyle, socioeconomic status, and compliance, were not taken into account. 
Disease characteristics were assessed by looking at differences in indication for 
transplantation and disease severity between the United States and the other OECD 
countries. Disease severity was assessed by the mean Model for End-Stage Liver Disease 
(MELD) score, United Network for Organ Sharing (UNOS) status, and Child-Pugh category 
depending on the available data. 
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As an indicator for the quality of the provider of the treatment, one-year patient survival 
rates after liver transplantation in the United States and other OECD countries were 
compared. As a second indicator for quality, the annual number of liver transplantations 
per center were compared. Centers were considered as having high volume when 
performing more than 20 transplantations annually14. As a third indicator for quality, the 
mean length of stay in the hospital after liver transplantation was compared between the 
United States and the other OECD countries. 
The health care systems of the United States and other OECD countries were compared on 
structural differences. The most important difference between the health care systems of 
the United States and other OECD countries is the availability of resources; that is, richer 
countries have theoretically more resources available for health care. By adjusting costs 
to gross domestic product (GDP) per capita, differences in available resources were taken 
into account. GDP per capita, as reported by the OECD in 2006, is a measure of the 
average level of economic activity. GDP was separately adjusted for the United States and 
the other OECD countries, weighted by the number of patients included. Furthermore, 
cost of liver transplantation was also adjusted for GDP at purchasing power parity (PPP). 
GDP at PPP was reported by the International Monetary Fund (IMF) in 2006. PPP is a 
currency conversion rate taking into account differences in price levels between countries 
by using the prices of a basket of 3000 consumer goods and services, government services, 
and investment goods. Adjustment for GDP at PPP was done separately for the United 
States and the other OECD countries, weighted by the number of patients included. Health 
care system characteristics, such as alternative treatment options, were not compared 
because there are no alternatives for liver transplantation. Furthermore, availability of 
care and waiting lists were not compared because every health care system has a waiting 
list for liver transplantation due to the limited availability of donor livers. 
Methodological characteristics of the economic evaluations were compared between the 
United States and the other OECD countries. Both the method of assessing cost of liver 
transplantation and the timing of the economic evaluation were considered relevant 
methodological characteristics. Concerning the method of assessing costs, a distinction 
was made between hospital charges, costs extracted from the hospital accounting system, 
costs calculated by using cost-to-charge ratios, microcosting, and Medicare fee. These five 
methods of assessing costs use different inclusion and valuation of cost components: (a) 
Hospital charges reflect the market price at which a hospital is willing to perform a 
service and may include profit; (b) cost-to-charge ratios are calculated by applying the 
ratio of the organization’s costs to its charges preferably differentiated by department; 
(c) the hospital accounting system estimates costs by internal cost attribution; (d) 
microcosting is based on identification, measurement, and valuation of individual 
resources; and finally (e) Medicare fee represents the reimbursement paid by Medicare 
(the U.S. national social insurance program) to a health care provider and is only 
applicable to U.S. articles. Timing of the economic evaluation was also examined because 
developments, such as diagnostics, surgery, experience, and use of medication may alter 
cost over time. The year of publication of the article was used to assess timing of the 
economic evaluation.  
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2.4 Costing methods 
In this study, only costs related to liver transplantation and initial hospital stay after 
transplantation were included. To enable comparison between the United States and 
other OECD countries, the overall mean cost of liver transplantations was used as an 
estimate. The arithmetic mean cost per liver transplantation was based on the mean cost 
per article, weighted by the number of patients included. Therefore, articles based on a 
large number of patients had a high impact on the arithmetic mean cost per liver 
transplantation. An estimated mean was calculated by the meta-analysis for the United 
States and other OECD countries. The estimated mean was used for cost comparison in 
this study. 
Professional fees accounted on average for less than 10% of total costs in two large studies 
4,15. Four U.S. articles excluded professional fees leading to a slight underestimation of 
costs. All the articles from other OECD countries included professional fees. 
All costs were presented in 2005 U.S. dollar value. Due to the difference in time between 
reported articles, a correction for inflation was made. All reported costs were adjusted by 
year of patient inclusion for U.S. inflation to the year 2005 (http://www.bls.gov/cpi/). 
Conversions were made by using the exchange rates on July 1, 2005, because this was the 
most recent year in which published costs were determined. The resulting exchange rates 
were as follows: € 1 equals US$ 1.1957, £ 1 equals US$ 1.7708, and 1 CAD equals 
US$ 0.805283. Euro zone currency before 2002, the year the Euro was introduced, was 
adjusted using the fixed conversion rates of the former national currencies. In this article 




3.1 Results systematic review 
From 2000 potentially relevant citations identified by our initial search strategy, 1829 
were not included in the systematic review because these citations did not discuss cost of 
liver transplantation (Figure 1). Of the remaining 171 citations the full articles were 
retrieved. After applying the exclusion criteria specified earlier, 141 articles were 
excluded. The majority of these articles (n = 120) were excluded because of lack of 
information on individual patients. Other reasons for exclusion were the use of identical 
patient-level data in other included studies (n = 11), costs only focused on donor 
evaluation (n = 4), studies of non-OECD countries (n = 3), and cost data only available for 
fewer than 10 transplantations (n = 3). A list of excluded articles with reasons for 
exclusion is available on request from the authors. The selection process eventually led to 
30 articles that were eligible for the systematic review4-6,9,13,15-39. Among the selected 
articles, three of them were written in a non-English language. No additional articles on 
cost of liver transplantation were found by checking the references of the selected 
articles. Also, after hand searching the indicated two journals, no additional articles were 
found, confirming that the initial search was comprehensive. 
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In Table 1, all included articles are ordered on year of publication and name of the first 
author. Besides the United States, studies were performed in eight different OECD 
countries. Even though five institutions participated in multiple articles, patient 
populations were different and could, therefore, be included. The included articles were 
published between 1990 and 2006 and included patients between March 1979 and June 
2005. The number of liver transplantations in the included articles ranged from 11 to 1621 
per article (median: 100). A total of 15 U.S. articles included 4629 liver transplantations 
compared to 1346 liver transplantations as discussed in 15 articles from the other OECD 
countries. In total, this systematic review and meta-analysis included 5975 liver 
transplantations from 30 articles. U.S. articles reported weighted arithmetic mean cost of 
US$ 174 490 per liver transplantation compared to US$ 108 934 for the other OECD 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2 Results from meta-analysis 
In the meta-analysis, eight U.S. articles (53%) and four OECD articles (27%) were included. 
The other articles did not report measures of spread. By applying a random-effects model, 
the estimated mean cost was US$ 179 143 (US$ 148 661 - 209 625) for the United States 
compared to US$ 99 405 (US$ 56 623 - 142 188) for the other OECD countries (Figure 2). 
High heterogeneity was observed in both groups11. The Q value in the United States was 
179 versus 45 for the other OECD countries (both p < 0.001) and the I2 was 96% versus 93%, 
respectively. The high heterogeneity confirmed the choice for the random-effects model. 
The second analysis included all articles in the random-effects model. The mean cost was 
US$ 163 438 (US$ 145 277 - 181 598) compared to US$ 103 548 (US$ 85 514 - 121 582) for 
the United States and other OECD countries, respectively (Figure 2). High heterogeneity in 
both groups was also indicated in the second analysis. The Q value in the United States 
was 374 versus 138 for the other OECD countries (both p < 0.001) and the I2 was 96% 
versus 90%, respectively. Sources of heterogeneity were explored by comparison of study 
characteristics. 
 
3.3 Comparison of study characteristics 
Cost differences according to patient characteristics 
The mean age reported in the 15 U.S. articles and 10 OECD articles was 47.6 years and 
45.2 years, respectively (Table 2). Four OECD articles reported only the median ages. The 
weighted mean of these median ages was 49.6 years. The majority of the recipients in the 
United States articles and the other OECD articles was male (57% vs. 59%). In the United 
States articles, 9% of the transplanted patients were pediatric recipients compared to 5% 
in the other OECD countries. 
 
Cost differences according to disease characteristics 
The indication for transplantation was reported in 12 U.S. articles (80%) and in 10 of the 
other OECD articles (67%). Table 2 shows that the U.S. articles reported more recipients 
with hepatitis C cirrhosis (26% vs. 18%), but less acute liver failure (3% vs. 9%) and primary 
biliary cirrhosis (4% vs. 15%) compared to the other OECD countries. One article reported 
higher costs for patients transplanted for alcoholic liver disease than patients transplanted 
for primary biliary cirrhosis and primary sclerosing cholangitis5. Another article reported 
that patients with acute liver failure had higher costs than patients with chronic liver 
failure38. 
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Figure 2. Meta-analysis of cost of liver transplantation with random effects model. Abbreviations: CI 
= confidence interval, US = United States, OECD = Organization for Economic Cooperation and 
Development. 
 
Information on disease severity before liver transplantation, as measured by the MELD 
score, UNOS status, or Child-Pugh category, was reported in 58% and 39% of the United 
States and other OECD articles, respectively. However, in both categories of articles, 
disease severity of recipients before transplantation was similar (Table 2). 
 
Cost differences according to quality of the provider of the treatment 
One-year patient survival rates between the United States and the other OECD countries 
were compared. Furthermore, 13 U.S. articles and 8 other OECD articles reported one-
year patient survival. In addition, only one U.S. article and two other OECD articles 
reported two-year patient survival rates, and these rates were used as well6,33,36. The 14 
U.S. articles reported mean one-year patient survival of 84%, and the other 10 OECD 
articles reported mean one-year patient survival of 80%. 
All United States and other OECD liver transplantations were performed in high-volume 
centers14. During the study period of the included studies, 100% and 99% of liver 
transplantations were performed in high-volume centers in the United States and other 
OECD countries, respectively. 
Mean length of hospital stay for liver transplantation could be assessed for 82% and 53% of 
the cases in the United States and the other OECD countries, respectively. The mean 
length of stay after liver transplantation was 30.4 days compared to 62.4 days for the 
United States and the OECD countries, respectively (Table 2). 
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Table 2. Characteristics of articles of cost of LTx in the United States and other OECD countries. 
Patient characteristics US Other OECD countries 
Gender (male %) 57% 59% 
Age (mean, years) 47.6 45.2 
Pediatric recipients (%) 9% 5% 
Disease characteristics   
Diagnosis   
   acute liver failure 3% 9% 
   chronic liver failure 83% 80% 
      of which: alcoholic liver disease 17% 14% 
      of which: hepatitis C cirrhosis 26% 18% 
      of which: primary biliary cirrhosis 4% 15% 
   tumor 1% 3% 
   metabolic and other 12% 8% 
MELD (mean) 21.6 22.1 
UNOS status 1 19% 22% 
UNOS status 2 31% 27% 
UNOS status 3/4 51% 51% 
Child-Pugh category A 13% 0% 
Child-Pugh category B 51% 44% 
Child-Pugh category C 35% 56% 
Quality of the provider   
One-year patient survival rate 84% 80% 
Centers > 20 LTx annually (%) 100% 99% 
Length of stay after LTx (mean, days) 30.4 62.4 
Different health care systems   
GDP $ 41 900 $ 35 480 
PPP index (other OECD countries = 100) 126 100 
Other OECD countries: Canada, France, Germany, Italy, Japan, Switzerland, the Netherlands, and 
United Kingdom. Abbreviations: US = United States, OECD = Organization for Economic Cooperation 
and Development, GDP = gross domestic product, PPP = purchasing power parity, MELD = model for 
end-stage liver disease, UNOS = United Network for Organ Sharing. 
 
Cost differences according to different health care systems 
The GDP of the United States is US$ 41 900 compared to the weighted mean GDP of the 
other OECD countries of US$ 35 480. A liver transplantation performed in the United 
States would cost an estimated US$ 138 396 if the GDP was the same as the GDP of the 
other OECD countries. This reduces the cost difference between the United States and the 
other OECD countries from 58% to 34% (Table 3). The PPP of the United States is 126% of 
the weighted mean PPP of the other OECD countries. Cost of a U.S. liver transplantation 
would be reduced to US$ 129 425 if the PPP was equal to the other OECD countries. This 
reduces the cost difference between the United States and other OECD countries even 
further to 25% (Table 3). 
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Table 3. Impact on mean cost per liver transplantation by correcting for GDP and GDP at PPP. 
Mean cost of liver transplantation US Other OECD countries 
Inflation-corrected $ 163 438 $ 103 548 
GDP per capita-corrected $ 138 396 $ 103 548 
GDP at PPP per capita-corrected $ 129 425 $ 103 548 
Other OECD countries: Canada, France, Germany, Italy, Japan, Switzerland, the Netherlands, and 
United Kingdom. Abbreviations: US = United States, OECD = Organization for Economic Cooperation 
and Development, GDP = gross domestic product, PPP = purchasing power parity. 
 
Cost differences according to methodology used in the economic evaluation 
Figure 3 shows the mean cost per liver transplantation for the five different methods of 
cost assessment. The preferred method to calculate costs of transplantation in the United 
States was by using hospital charges, whereas the other OECD countries preferred 
microcosting. However, note that in all U.S. articles, cost of liver transplantation was 
similar, notwithstanding the method of cost assessment used. Only cost-to-charge ratios 
led to lower U.S. costs. The articles from the other OECD countries showed only a small 




Figure 3. Mean cost per liver transplantation for different methods of cost assessment. Numbers 
within bars represents number of patients used to estimate the mean. Abbreviations: US = United 







































































The timing of the economic evaluation differed slightly between the United States and the 
other OECD countries. The first U.S. article was published in 199635 compared to 1990 for 
the other OECD countries9. The most recent articles included in this meta-analysis for the 
United States4,39 and the other OECD countries26,27 were published in 2006. Figure 4 shows 
the mean arithmetic cost per transplantation for the 30 articles with the size of the circle 
depicting the number of transplantations. Both in the United States and in the other OECD 
countries, cost of liver transplantation showed a decline of US$ 500 and US$ 690 per year, 
respectively. The difference in cost of liver transplantation between the United States and 
the other OECD countries remained quite stable in the past two decades. 
 
 
Figure 4. Mean cost per liver transplantation in different health care systems. The size of the circle 
depicts the number of patients in the study. Abbreviations: US = United States, 
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4 DISCUSSION 
This comprehensive review and meta-analysis were conducted to summarize the research 
to date and to examine the differences in cost of liver transplantation between the United 
States and other OECD countries. An insight into these cost differences may assist health 
care decision makers in not only gaining an insight into the cost of liver transplantation in 
different health systems, but critically scrutinize their own policy as well. Furthermore, 
insight into cost of liver transplantation may not only support increased allocation of 
health care resources to existing transplant programs but also may aid in the discussion 
about the introduction or expansion of this effective therapy in emerging and developing 
countries and regions. 
So far, the economical consequences of liver transplantation were explored scarcely. 
Available articles concerned heterogeneous groups of patients, varied widely in the 
included number of patients, used different methods of cost assessment, and considered 
different eras in liver transplantation. This heterogeneity leads to difficulties in the 
interpretation of cost differences between U.S. articles and articles from the other OECD 
countries. The present study is the first meta-analysis comparing the United States with 
the other OECD countries by combining a total of 5975 liver transplantations. Our study 
revealed that a liver transplantation performed in the United States was more expensive 
than a liver transplantation performed in other OECD countries. 
The results of the meta-analysis show that the pooled estimate cost of US$ 163 438 
(US$ 145 277 - 181 598) for liver transplantations in the United States differs significantly 
from the pooled estimate of US$ 103 548 (US$ 85 514 - 121 582) from the other OECD 
countries. In addition to a difference between the United States and other OECD 
countries, there is also large heterogeneity within the United States and among the other 
OECD countries. The random-effects model on the selection of articles with primary data 
on measures of spread led to the same conclusions as the all-inclusive model that included 
all articles. While the estimated mean was similar, the confidence interval of the model 
that included all articles was smaller due to the higher number of included articles. The 
mean costs of transplantations as incurred in the United States and in the other OECD 
countries were still significantly different from each other, even with all articles included. 
Thus, the liver transplantation cost difference between the United States and the other 
OECD countries can be considered significant, despite the large variation within both 
groups. 
Recipient characteristics showed similar gender and age distribution between the United 
States and the other OECD countries. The 4% difference between the proportion of 
pediatric recipients in the United States and other OECD countries could be explained by 
the two U.S. articles that exclusively examined pediatric recipients13,20. However, 
reported mean cost of liver transplantation in pediatric recipients in these two articles 
was similar to mean costs in other U.S. articles. Therefore, it was unlikely that age, 
gender, or the difference between adult and pediatric recipients caused a higher 




Disease characteristics were slightly different when assessing the indication for liver 
transplantation.In a recent article comparing the United States with the United Kingdom 
and Ireland10, a similar distribution of indications was presented. Higher costs were 
reported for alcoholic liver disease5 and for acute liver failure38. However, the U.S. 
articles included in this review reported only slightly more alcoholic liver disease than 
that reported in the articles from the other OECD countries (17% vs. 14%) while acute liver 
failure was reported less often as an indication (3% vs. 9%). Since mean MELD score, UNOS 
status, and Child-Pugh class were also similar between the United States and other OECD 
countries, it was not likely that disease characteristics were an explanation for the higher 
cost in the United States. 
The quality of the provider of the treatment was assessed by the results after 
transplantation and the volume of transplantations. Unfortunately, the majority of articles 
reported no graft survival rates or quality-adjusted life years. Therefore, only patient 
survival rates could be assessed. A small difference between the one-year patient survival 
rates of the United States and the other OECD countries was found (84% vs. 80%). The 
small difference may be explained by the inclusion of the three OECD articles published 
between 1990 and 1993, which reported lower survival9,19,31. In literature, a similar one-
year patient survival after liver transplantation has been reported in the United States, 
Canada, and the United Kingdom 2,10. The majority of liver transplantations of the United 
States and other OECD countries was performed in a high-volume center. The U.S. articles 
reported approximately half the length of stay in comparison to that mentioned in articles 
from the other OECD countries, probably due to a different discharge policy (Table 2). 
However, the shorter length of stay of U.S. patients did not translate to lower costs. 
Furthermore, it is difficult to derive quality differences from length of stay without 
information on the required care after discharge. In conclusion, a cost difference arising 
out of the quality of the provider of the treatment was not likely due to similar one-year 
patient survival, a similar number of high-volume centers, and an inverse relationship 
between costs and length of stay in the United States compared to other OECD countries. 
Health care system characteristics turned out to be the most important explanation for 
the cost differences in liver transplantation. Corrections for GDP per capita and PPP led to 
major reduction of the cost difference between the United States and other OECD 
countries. According to a report of the World Health Organization40, the United States 
spends 15.2% of GDP on health care, compared to a weighted mean of 9.4% of GDP for the 
other OECD countries. Therefore, the higher cost of liver transplantation in the United 
States compared to other OECD countries was in line with overall differences in cost of 
health care. The higher cost of health care in the United States consisted primarily of 
higher prices of hospital stay, physician services, and pharmaceuticals1,41. Other 
explanations such as administrative complexity, malpractice litigation, and absence of 
supply constraints also added to the higher cost of health care in the United States, but to 
a lesser extent1,41. These explanations for higher cost of health care were reflected in GDP 
and PPP as well as in the proportion of GDP spent on health care. Health care system 
explanations being exclusively related to organ transplantation could be attributed to 
differences in costs as well. 
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A policy in the allocation of organs leading to transplantation of severely affected patients 
may lead to worse outcome, with more complications and reinterventions eventually 
leading to higher costs. Since February 2006, the United States has been using the MELD 
score for allocation of donor livers. Half of the OECD countries included in this study have 
recently adopted the MELD system as well. However, allocation systems were different 
between countries at the time of publication of the articles. In addition, changes in donor 
liver allocation within countries makes it very difficult to assess the impact of allocation 
systems on costs. 
Methodology used in the economic evaluation was assessed by looking at the method of 
cost assessment and timing of the publication. Different methods of cost assessment were 
used within the articles from the United States and other OECD countries. Regardless of 
using hospital charges, hospital accounting system, microcosting, or Medicare fee, U.S. 
articles reported higher costs than other OECD articles. Two U.S. articles used cost-to-
charge ratios and due to a mean cost-to-charge ratio of 0.56, these costs were clearly 
lower. Converting charges into hospital costs is becoming more commonplace in U.S. 
studies but should still be used with caution42. In addition, mean cost of liver 
transplantation seemed to slightly decrease over time for both the United States and for 
the other OECD countries. Possible explanations for these slightly decreasing costs were 
increased experience leading to a decline in morbidity-related costs and a higher efficacy 
of the transplant-related procedures resulting in less resource utilization15. Important to 
note, however, is that by combining slightly declining costs over time with increased 
patient survival after liver transplantation, cost-effectiveness improves leading in turn to 
better value for money. Methodology used in the economic evaluation was not an 
explanation for the cost difference between the United States and the other OECD 
countries. A limitation of this review was the unavailability of primary data. Therefore, 
meta-analysis was not straightforward. Another limitation of this review was the 
restricted scope of costs included. Costs of all phases of the liver transplantation process 
were retrieved from articles. However, information on cost of the donor, recipient 
selection, recipient waiting, and outpatient follow-up were absent or too limited to be of 
any use for a sensible comparison. Costs related to these other phases will add to the 
total cost, even though the costs of liver transplantation and clinical follow-up will 
comprise the majority of total costs. A concern for future comparisons is the impact of the 
current decline in value of the US dollar compared to other major currencies. The studies 
included in this meta-analysis were performed between 1990 and 2005 with relatively 
stable exchange rates between the currencies. However, the impact of a decline in value 
of the US dollar may alter the cost difference between health care interventions 




Correcting costs for GDP per capita and PPP may reduce variation due to exchange-rate 
volatility. Future studies are needed to quantify the evolving cost-effectiveness of liver 
transplantation to start or expand this effective therapy in new regions and centers across 
the world. More information is needed on the impact of incentives for physicians and 
hospitals to provide such therapies. With future studies reporting on cost of liver 
transplantation, stratification might become possible regarding indication for liver 
transplantation or regarding different donor sources. More information is also needed to 
specify costs of the other phases of liver transplantation, such as costs incurred for 
recipient screening, on the waiting list, and during long-term follow-up of the recipient. 
The prospective Dutch COLT study (Cost and Outcome of Liver Transplantation) is 
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